巴曲抗栓酶治疗急性心肌梗死

目的：观察巴曲抗栓酶对急性心肌梗死（ＡＭＩ）的疗效。方法：２４例ＡＭＩ病人（男性１８例，女性６例；年龄６９±ｓ９ａ），其中８８％为发病１２ｈ内入院。入院即刻给阿司匹林０．３ｇ，ｐｏ，ｑｄ×３ｄ，再改为０．１ｇ，ｐｏ，ｑｄ；入院即ｉｖ输注巴曲抗栓酶２０ＢＵ溶于０．９％氯化钠液１００ｍＬ，１ｈ内滴完，以后每隔１ｄ（即入院ｄ３，ｄ５）再用巴曲抗栓酶１０ＢＵ，１次。结果：冠状动脉再通率为５０％（６ｈ内入院者为６９％），住院病死率为１２％，未见出血等不良反应。用药后凝血因子Ｉ有显著降低。结论：巴曲抗栓酶治疗ＡＭＩ是安全有效的。

Batroxobin (DF-521) in treating acute myocardial infarction

AIM:To study the effect of batroxobin(DF-521)in treating acute myocardial infarction(AMI).METHODS:Twenty-four patients with AMI(M 18,F6;age 69± s 9 a,88% patients were admitted in 12 h after attack). Aspirin 0.3g,po,was given immediatly after admission, then 0.3g,po,qd×3 d,then 0.1g,po,qd.On the day of admission,batroxobin (DF-521) 20 BU dissolved in 100 mL of 0.9% sodium chloride was given intravenously in 1h, then batroxobin (DF-521) 10 BU,iv,qOP(on d 3,d5) ,total dosage 40 BU. RESULTS:Recanalization of coronary artery occurred in 50 % (69 % in patients admitted in 6 h after attack).Mortality in hospital was 12%. No adverse reactions such as hemorrhage were found.Fibrinogen was reduced after batroxobin(DF-521) .CoNCLUSION :Batroxobin is safe and effective for the treatment of AMI.